Low molecular weight heparin vs vitamin K antagonist (VKA): Recurrent VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
LMWH vs VKA Incidence of recurrent VTE (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty). Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… (2017) · Cochrane Headline outcomes only | Peto OR 0.83 [0.6, 1.15] | 16 studies · 3299 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.